A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)

Trial Profile

A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Cardiomyopathies; Chronic heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CUPID; CUPID-1
  • Sponsors Celladon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jun 2015 According to a Celladon Corporation media release, company has announced the suspension of its plans for research or development of MYDICAR program.
    • 20 Nov 2013 Final results at 3 years presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top